Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Roche Holding (UK) is the holding company for Roche Products Limited and Roche Diagnostics Limited. The two UK subsidiaries develop and manufacture various products and equipment for the diagnosis and treatment of disease. Its pharmaceuticals include Copegus, a hepatitis C therapy; HIV inhibitor Fuzeon; and breast cancer therapy Herceptin. The firm's diagnostics arm makes a variety of consumer and professional tests, including Accu-Chek glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics.

Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. United's products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. United's Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. United's pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases.

Roche Holding Ltd. company operates two segments, pharmaceuticals and diagnostics, and sells its products in more than 150 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Herceptin, anemia treatment NeoRecormon/Epogin, hepatitis drug Pegasys, transplant drug CellCept, obesity treatment Xenical, and Tamiflu, which is used to prevent and treat influenza, including avian strains. The company markets many of its bestsellers through subsidiary Genentech and affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers advanced DNA tests, diabetes monitoring supplies, and point-of-care diagnostics used in a variety of health care settings.

Amicus Therapeutics, Inc. company was founded in 2002 and is based in Cranbury, New Jersey. Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company’s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

The health care products subsidiary of Bayer AG, Bayer HealthCare develops and manufactures products for humans and animals. Bayer HealthCare operates through four divisions: Pharmaceuticals (represented by Bayer Schering Pharma and Bayer Healthcare Pharmaceuticals); Consumer Care (OTC medications); Animal Health (veterinary drugs); and Medical Care (diagnostic equipment makers including Diabetes Care and MEDRAD). Bayer HealthCare's better-known products include YAZ birth control pills, antibiotic Avelox, erectile dysfunction treatment Levitra, Bayer Aspirin, Alka-Seltzer, One-A-Day vitamins, and the flea preventative Advantage.

Pacific Biosciences, Inc. company was founded in 2004 and is based in Menlo Park, California. Pacific Biosciences, Inc. operates as a biotechnology company in North America. The company develops a transformative single-molecule (SMRT) DNA sequencing platform, which enables the observation of natural DNA synthesis by a DNA polymerase as it occurs; simplifies the resequencing of complex genomes; and the characterization of structural variation, including insertions, deletions, and rearrangements. Its products include SMRT chip, which enables the observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a signal-to-noise ratio; and Phospholinked nucleotides that produce a natural DNA strand through DNA synthesis. Its product applications include de novo sequencing and resequencing. Pacific Biosciences, Inc. was formerly known as Nanofluidics, Inc.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.